Bajaj Healthcare Ltd

Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara, Gujarat; one manufacturing plant of finished formulations in Vadodara, Gujarat; and one manufacturing plant of intermediates in Tarapur, Maharashtra. Bajaj Healthcare reported standalone net profit of Rs 11.18 crore in Q4 FY25 as compared with net loss of Rs 29.92 crore posted in Q4 FY24. However, revenue from operations jumped 15.36% year-on-year (YoY) to Rs 154.47 crore in the quarter ended 31 March 2025. Powered by Capital Market - Live

Bajaj Healthcare announced that the Board of Directors of the Company at its meeting held on 26 May 2025, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 20%) , subject to the approval of the shareholders.Powered by Capital Market - Live

However, revenue from operations jumped 15.36% year-on-year (YoY) to Rs 154.47 crore in the quarter ended 31 March 2025. The company reported a profit before tax of Rs 11.72 crore in Q4 FY25, compared to a pre-tax loss of Rs 35.15 crore in the corresponding quarter of the previous year. Total expenses increased by 19.17% YoY to Rs 156.32 crore in Q4 FY25. Cost of material consumed was Rs 100.49 crore (up 98.47% YoY), while employee expenses stood at Rs 15.71 crore (up 47.92% YoY) and finance costs came in at Rs 6.08 crore (up 1.16% YoY) during the period under review. On a full-year basis, the company reported a standalone net profit of Rs 39.50 crore in FY25, as against a net loss of Rs 83.79 crore in FY24. Revenue from operations jumped 14.61% YoY to Rs 542.60 crore in FY25. Meanwhile, the company's board has recommended a final dividend of Rs 1 per equity share for the financial year 2024-25, subject to the approval of the shareholders at the ensuing Annual General Meeting of the company. Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara, Gujarat; one manufacturing plant of finished formulations in Vadodara, Gujarat; and one manufacturing plant of intermediates in Tarapur, Maharashtra. The counter tumbled 7.75% to Rs 555.60 on the BSE. Powered by Capital Market - Live

Net profit of Bajaj Healthcare reported to Rs 11.18 crore in the quarter ended March 2025 as against net loss of Rs 29.92 crore during the previous quarter ended March 2024. Sales rose 15.36% to Rs 154.47 crore in the quarter ended March 2025 as against Rs 133.90 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 39.50 crore in the year ended March 2025 as against net loss of Rs 83.79 crore during the previous year ended March 2024. Sales rose 14.61% to Rs 542.60 crore in the year ended March 2025 as against Rs 473.42 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales154.47133.90 15 542.60473.42 15 OPM %7.6211.98 -15.1916.11 - PBDT19.2616.48 17 73.9355.27 34 PBT11.739.18 28 46.0127.65 66 NP11.18-29.92 LP 39.50-83.79 LP Powered by Capital Market - Live

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live

The agency has affirmed the company's short-term rating at 'IND A2+'. India Ratings and Research stated that the outlook revision reflects strong growth in BHL's revenue and profitability in 9MFY25, coupled with the equity infusions during FY25-FY26 through preferential equity share allotment and share warrants, leading to the repayment of debt and funding for capex requirements. India Ratings notes the equity infusions have led to a significant improvement in the company's credit metrics, with its leverage remaining below 2x over the near to medium term. The ratings reflect BHL's improving business mix, led by diversification in higher margin business formulations coupled with revenue emanating from contract development and manufacturing organisation (CDMO) business which has a long term visibility of supplies and profitability. The agency notes although active pharmaceutical ingredient (API) pricing has stabilised, competition from China in its key products will continue to remain a monitorable. As per the management, BHL has backward integration in its large molecules which will offset any further pricing challenges. The agency will monitor the improvement in the working capital cycle and its impact on the credit metrics in the near term. India Ratings further said that a significant increase in the scale of operations and the profitability while improving the gross working capital cycle, resulting in the net leverage reducing below 2.0x, on a sustained basis, could lead to a positive rating action. However, a significant decline in the scale of operations and the EBITDA margins, along with deterioration in the gross working capital cycle, liquidity position and overall credit metrics, with the net leverage remaining above 3.0x, all on a sustained basis, will be negative for the ratings. Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara in Gujarat: one manufacturing plant of finished formulations in Vadodara, Gujarat and one manufacturing plants of intermediates in Tarapur, Maharashtra. The scrip shed 0.86% to currently trade at Rs 553.60 on the BSE. Powered by Capital Market - Live

The acquisition, valued at Rs 10.85 crore through a cash consideration, involves 100% control of Genrx Pharmaceuticals. GenRx Pharmaceuticals is a WHO-GMP certified pharmaceutical manufacturer engaged in the production of allopathic formulations, nutraceuticals, and natural products. The company operates a manufacturing facility located at MIDC Sinnar, Nashik, with the capability to produce solid and semi-solid dosage forms such as tablets, capsules, external preparations, cosmetic products, and nasal sprays. Anil Jain, managing director, Bajaj Healthcare, said: 'The acquisition of Genrx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities. This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth. Completion of the acquisition is expected within 3'6 months, subject to requisite FDA and other regulatory approvals. This addition will enable us to expand our manufacturing portfolio, paving the way for long-term value creation and strengthening our footprint in the pharmaceutical sector. Bajaj Healthcare a leading manufacturer of apis, intermediates and formulations. It specializes in manufacturing of intermediates, API, formulations & nutraceuticals. Powered by Capital Market - Live

Net profit of Bajaj Healthcare reported to Rs 11.72 crore in the quarter ended December 2024 as against net loss of Rs 2.20 crore during the previous quarter ended December 2023. Sales rose 13.10% to Rs 122.79 crore in the quarter ended December 2024 as against Rs 108.57 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales122.79108.57 13 OPM %17.6217.98 - PBDT18.5013.67 35 PBT11.656.32 84 NP11.72-2.20 LP Powered by Capital Market - Live

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live

Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Pimavanserin, marketed globally as NUPLAZID, has become a preferred treatment in the US antipsychotic segment. In a recent update, Acadia Pharmaceuticals announced that NUPLAZID, along with its other brand DAYBUE, is projected to generate more than $1 billion in net sales in 2025. The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product's availability in the domestic market. Anil Jain, managing director, Bajaj Healthcare, said: 'The approval marks a major milestone for Bajaj Healthcare. The growing success of NUPLAZID in the US underscores the global demand for this innovative therapy, and we are confident that its introduction in India will be a transformative advancement in the antipsychotic segment. This move further solidifies our presence in the central nervous system (CNS) segment and highlights our dedication to advancing healthcare solutions in India.' Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The company had reported standalone net profit of Rs 94.64 crore in Q2 FY25 as compared with net loss of Rs 34.60 crore in Q2 FY24. Revenue from operations jumped 31.5% YoY to Rs 133.08 crore in Q2 FY25. The scrip fell 2.46% to currently trade at Rs 640.25 on the BSE. Powered by Capital Market - Live